We were delighted to welcome Dr. Dan Williams, CEO and co-founder of SynaptixBio, a pioneering biotech company on a mission to develop life-changing treatments for children affected by devastating brain disorders, onto the bio hub. With over two decades of experience in the biotech and pharmaceutical industries, Dan has led teams from the lab bench to global clinical programs, and now he’s tackling one of the rarest and most challenging neurological diseases: TUBB4A-related leukodystrophies, including the severe H-ABC form.Under Dan’s leadership, SynaptixBio is leveraging cutting-edge antisense oligonucleotide (ASO) technology to silence disease-causing genes and bring hope to families with no existing treatment options. In just a few years, his team has secured orphan drug designations, raised significant funding, and is driving toward clinical trials with an urgency that reflects the needs of the patients they serve.We’ll talk to Dan about his journey from scientist to biotech CEO, the science behind SynaptixBio’s approach, and what it takes to bring a rare disease therapy from concept to clinic.